An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.

Rheumatology (Oxford, England)

Volumn 50, Issue 6, 2011, Pages 1131-1136

  Prince, Femke H M ^a   de Bekker Grob, Esther W ^b   Twilt, Marinka ^b   van Rossum, Marion A J ^b   Hoppenreijs, Esther P A H ^b   ten Cate, Rebecca ^b   Koopman Keemink, Yvonne ^b   Gorter, Simone L ^b   Raat, Hein ^b   van Suijlekom Smit, Lisette W A ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; NETHERLANDS; REGISTER;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; MALE; NETHERLANDS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES;

EID: 84856636445     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq432     Document Type: Article

References (0)